Ophthalmic solution Ofloxacin

Ofloxacin 0.03% ophthalmic solution has also been shown to be effective in the treatment of corneal ulcers. Studies demonstrate that ofloxacin causes less burning... 

Sensory systems Taste Levofloxacin ophthalmic solution 1.5% in 100 patients has been compared with ofloxacin ophthalmic... 

Walters T, Rinehart M, Krebs W, Holdbrook M. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers. Cornea 2010 29 263-8. 

ONE-YEAR OCULAR TOXICITY STUDY OF OFLOXACIN OPHTHALMIC SOLUTION IN BEAGLE DOGS... 

Ocular toxicity and systemic adverse effects of 0.3% ofloxacin ophthalmic solution (0.3%OFLX) which was administered 3 times daily for one year were studied in dogs. 

In the present study, we examined ocular toxicity of ofloxacin ophthalmic solution (3 times daily for one year application) in beagle dogs with pigmented eyes. In order to investigate the effects of melanin-bound ofloxacin on retinal function and the effect of ofloxacin on central nerve system, electroretinogram (ERG) was recorded and behavior of dogs was observed during test periods. 

Ofloxacin synthesized by Daiichi Pharmaceutical Co.,Ltd (Tokyo, Japan), was made into 0.3% ophthalmic solution (0.3%OFLX). 0.3%OFLX used had been confirmed to be stable for more than 3 years at room temperature. The vehicle for the above 0.3%OFLX was used as the negative control. 

Ten dogs with normal eyes and well acclimatized to ERG were selected and assigned to 2 groups with no biased distribution of body weight. The negative control, the vehicle for ofloxacin ophthalmic solution, and the test ophthalmic solution, 0.3%OFLX, were applied topically to the conjunctival sac bilaterally for 12 months (instillation for 5 days weekly) in the respective groups. 

Y. Mitsui, S. Sakuragi, 0. Tamura, M. Abe, I. Watanabe, M. Ueno, K, Choshi, H. Sakata, T. Suehiro, N. Ohoba, S. Fujita, Y. Miyazono, K. Sasaki, T. Yamamura, N. Watanabe, M. Uyama, K, Kanai, T. Tokuyama, H. Miyatani, M. Itoi, Y. Kodama, H. Tasaka, R. Manabe, Y Ohashi, Y. Shimomura, K. Segawa, K. Nishiyama, K. Norose, S. Inoue, K. Matsumura, M. Ooishi, F. Sakaue, A. Oomomo, J. Hara, S. Harino, J. Tsutsui, H. Kimura, S. Inoue, M. Higashitsutsumi, M. Sakamoto, T. Miwatani and T. Onoda, 1986, Effect of ofloxacin ophthalmic solution in the treatment of external bacterial infections of the eye. Foil. Ophthalmol Jpn., 37 1115. 

Co-administration of ofloxacin and chitosan in eyedrops increased the bioavailabUity of the antibiotic [290]. Trimethyl chitosan was more effective because of its solubility (plain chitosan precipitates at the pH of the tear fluid). On the other hand, N-carboxymethyl chitosan did not enhance the corneal permeability nevertheless it mediated zero-order ofloxacin absorption, leading to a time-constant effective antibiotic concentration [291]. Also W,0-carboxymethyl chitosan is suitable as an excipient in ophthalmic formulations to improve the retention and the bioavailability of drugs such as pilocarpine, timolol maleate, neomycin sulfate, and ephedrine. Most of the drugs are sensitive to pH, and the composition should have an acidic pH, to enhance stability of the drug. The delivery should be made through an anion exchange resin that adjusts the pH at around 7 [292]. Chitosan solutions do not lend themselves to thermal sterilization. A chitosan suspension, however. 

---